Cutaneous Lupus Erythematosus Market Report 2024

The cutaneous lupus erythematosus market size has grown rapidly in recent years. It will grow from $2.01 billion in 2023 to $2.24 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth during the historic period can be attributed to government and private funding, the expansion of healthcare infrastructure, increased awareness and education, improved support systems for patients, and the rising prevalence of autoimmune disorders.

The cutaneous lupus erythematosus market size is expected to see rapid growth in the next few years. It will grow to $3.5 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The anticipated growth during the forecast period can be attributed to rising investments in research and development, regulatory approvals and support, an aging population, improved patient education and awareness campaigns, and global market expansion. Major trends for this period include the expansion of telemedicine, enhanced patient monitoring and management, technological integration in healthcare, growth in personalized and precision medicine, and the use of genomic and proteomic technologies.

The increasing prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market in the future. Skin infections occur when microorganisms such as bacteria, fungi, or viruses invade and multiply within the skin, causing various symptoms and discomfort. These infections trigger an immune response, leading to inflammation as the body attempts to combat the infection. In individuals with CLE, this heightened immune response can exacerbate symptoms by targeting the skin cells. For example, in September 2022, according to the UK Health Security Agency (UKHSA), a UK-based national executive agency, the proportion of Methicillin-resistant Staphylococcus aureus (MRSA) cases linked to skin and soft tissue infections rose to 33.7% in 2022 from the previous year. Additionally, MRSA cases increased by 25.7% during the financial year from April 2020 to March 2021. Consequently, the rising incidence of skin infections is expected to boost the growth of the cutaneous lupus erythematosus market.

Key players in the cutaneous lupus erythematosus market are focusing on developing innovative monoclonal antibody treatments to enhance efficacy, improve patient outcomes, and provide more targeted and convenient therapies. Monoclonal antibody treatments use identical antibodies designed to target specific proteins or cells involved in disease processes, including autoimmune disorders such as lupus. For instance, in August 2021, AstraZeneca Plc, a UK-based pharmaceutical and biotechnology firm, introduced Saphnelo (anifrolumab), which was approved by the Food and Drug Administration (FDA) for treating adults with moderate to severe systemic lupus erythematosus (SLE) who are on standard therapy. Saphnelo is a pioneering type I interferon receptor antibody that binds to subunit 1 of the type I interferon (IFN) receptor, effectively inhibiting type I IFN activity. Since heightened type I IFN signaling is associated with increased disease activity and severity, Saphnelo is undergoing regulatory review for lupus erythematosus in the European Union (EU) and Japan. A Phase III trial with subcutaneous delivery has begun, with additional Phase III trials planned for lupus nephritis and cutaneous lupus erythematosus.

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition is expected to advance Amgen's objective of providing innovative treatments for rare diseases and strengthen its portfolio in inflammation therapeutics. Horizon Therapeutics plc, based in Ireland, is a biopharmaceutical company specializing in medicines for rare diseases, including lupus erythematosus.

Major companies operating in the cutaneous lupus erythematosus market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Limited, Allergan Inc., LEO Pharma A/S, Glenmark Pharmaceuticals Limited.

North America was the largest region in the cutaneous lupus erythematosus market in 2023. The regions covered in the cutaneous lupus erythematosus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cutaneous lupus erythematosus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cutaneous lupus erythematosus (CLE) is a chronic autoimmune skin disease marked by inflammation that can cause various skin lesions, photosensitivity, and potential scarring. Often associated with systemic lupus erythematosus (SLE), CLE primarily affects the skin. The main goals of treatment are to reduce inflammation, manage symptoms, and prevent flare-ups.

The primary types of cutaneous lupus erythematosus include acute, subacute, intermittent, and chronic forms. Acute cutaneous lupus erythematosus (ACLE) is characterized by sudden and severe skin reactions, often triggered by sun exposure. Symptoms typically feature a distinctive 'butterfly' rash across the cheeks and nose, as well as red, scaly patches on other sun-exposed areas. Drug classes for treatment include retinoids, corticosteroids, immunosuppressants, antimalarial drugs, and others, with administration routes such as oral, injections, and topical applications. The end users of these treatments include hospitals, specialty clinics, homecare settings, and others.

The cutaneous lupus erythematosus market research report is one of a series of new reports that provides cutaneous lupus erythematosus market statistics, including cutaneous lupus erythematosus industry global market size, regional shares, competitors with an cutaneous lupus erythematosus market share, detailed cutaneous lupus erythematosus market segments, market trends and opportunities, and any further data you may need to thrive in the cutaneous lupus erythematosus industry. This cutaneous lupus erythematosus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cutaneous lupus erythematosus market consists of revenues earned by entities by providing services such as diagnostic testing services, treatment administration services, patient monitoring, and management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cutaneous lupus erythematosus market also includes sales of pharmaceuticals, biologics, immunomodulators, diagnostic tests, and medical devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.